Lenz Therapeutics (LENZ): BML Investment Partners, L.P. now owns 6.7% of LENZ as a passive investor 6.7%

6.7%

Stake

2.11M

Shares owned

Stake as of

Nov 2, 2026

Filed

Nov 4, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 21, 20265% stakeMillennium Management LLC reported a passive stake (13G) of 3.7%
2. Oct 27, 20265% stakeBlackRock Portfolio Management LLC reported a passive stake (13G) of 5.2%
3. Oct 28, 2026Company filing · Form 8-K · Results, RestructuringAnnounced job cuts, closures or a restructuring, and changed a top executive or board member (and 1 more item)“On October 28, 2026, the Company announced that Evert Schimmelpennink, the Company’s President and Chief Executive Officer (“CEO”), will transition from his roles as President and CEO effective December 1, 2026 (the “CEO Transition Date”), with Daniel Chevallard, the Company’s current Chief Financial Officer, to succeed him as Interim President and CEO as of such date.”
4. Oct 29, 2026Insider · 1 personInsiders: 3 sales (~$9.1M)
5. Nov 2, 20265% stakeRA Capital Management, L.P. filed an activist stake (13D) of 0.2%

What came next

1. Nov 4, 20265% stakeBML Investment Partners, L.P. reported a passive stake (13G) of 6.7%
2. Nov 5, 20265% stakeFMR LLC reported a passive stake (13G) of 2.0%

How to read SEC Schedule 13G

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Lenz Therapeutics

For Lenz Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 4 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LENZ page.

How this filing works

• Schedule 13D vs 13G

Other disclosures at Lenz Therapeutics

• SEC Schedule 13GNov 5, 2026
• SEC Form 4Nov 2, 2026
• SEC Form 4Nov 2, 2026
• SEC Form 4Nov 2, 2026
• SEC Schedule 13DNov 2, 2026
• SEC Schedule 13GOct 21, 2026

Everything OQRO holds on this company is on its LENZ page.